Research graph
References from Effectiveness of a Molecular Tumor Board in Making Personalized Treatment Recommendations for Patients with Advanced Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1200/jco.21.02767
10.1200/jco.21.02767 · External reference
Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment
10.21037/atm-25-34 · 2025 · External reference
10.1200/po.18.00105
10.1200/po.18.00105 · External reference
10.1038/s44320-025-00125-1
10.1038/s44320-025-00125-1 · External reference
10.1056/nejmoa2115022
10.1056/nejmoa2115022 · External reference
10.1056/nejmoa1914609
10.1056/nejmoa1914609 · External reference
10.1056/nejmoa1413513
10.1056/nejmoa1413513 · External reference
10.1056/nejmoa1814017
10.1056/nejmoa1814017 · External reference
10.1016/s0140-6736(10)61121-x
10.1016/s0140-6736(10)61121-x · External reference
HER2-directed therapy improves urothelial cancer outcomes
10.1038/s41571-025-01089-9 · 2025 · External reference
10.1056/nejmoa2112431
10.1056/nejmoa2112431 · External reference
10.1016/j.trecan.2025.04.015
10.1016/j.trecan.2025.04.015 · External reference
10.1158/1078-0432.ccr-18-4070
10.1158/1078-0432.ccr-18-4070 · External reference
10.3389/fonc.2023.1252516
10.3389/fonc.2023.1252516 · External reference
10.1056/nejmoa2505783
10.1056/nejmoa2505783 · External reference
The need for molecular tumor boards
10.1038/s41591-025-03892-4 · 2025 · External reference
Molecular tumour boards — current and future considerations for precision oncology
10.1038/s41571-023-00824-4 · 2023 · External reference
10.1016/j.annonc.2024.04.005
10.1016/j.annonc.2024.04.005 · External reference
10.1016/j.annonc.2020.07.014
10.1016/j.annonc.2020.07.014 · External reference
Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
2022 · External reference
10.1038/s41416-022-02120-x
10.1038/s41416-022-02120-x · External reference
Molecular tumor board in patients with metastatic breast cancer
10.1007/s10549-024-07535-z · 2025 · External reference
PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation
10.1080/14796694.2025.2557176 · 2025 · External reference
10.3390/cancers17152435
10.3390/cancers17152435 · External reference
10.1056/nejmoa2202809
10.1056/nejmoa2202809 · External reference
10.1097/ede.0b013e3181577511
10.1097/ede.0b013e3181577511 · External reference
